Life sciences

The South and Central America cell therapy instruments market is expected to reach US$ 462.05 million in 2027 from US$ 1,074.99 million in 2019

Branches of biology, Life sciences, Biology, Biotechnology, Stem cells, Cell biology, Gene therapy, Cell therapy, Therapy
Tuesday, November 24, 2020 - 4:40pm

NEW YORK, Nov. 24, 2020 /PRNewswire/ -- The South and Central America cell therapy instruments market is expected to reach US$ 462.05 million in 2027 from US$ 1,074.99 million in 2019.

Key Points: 
  • NEW YORK, Nov. 24, 2020 /PRNewswire/ -- The South and Central America cell therapy instruments market is expected to reach US$ 462.05 million in 2027 from US$ 1,074.99 million in 2019.
  • The surge in the number of cell therapy transplantation procedures, growing research and development activities, and rising investments in building production facilities for cell and gene therapy products drive the growth of the South and Central America cell therapy instruments market.
  • On the basis of cell type, the cell therapy instruments market is segmented into animal cells and human cells.
  • Based on enduser, the South and Central America cell therapy instruments market is segmented into life science research companies, research institutes, and other end users.

Oligonucleotide Synthesis Markets, 2025 - Use of Synthesized Oligonucleotides in Molecular Diagnostics and Clinical Applications Driving Growth - ResearchAndMarkets.com

Biotechnology, Pharmaceutical, Genetics, Health, Nucleic acids, Branches of biology, Molecular biology, Life sciences, Biology, Oligonucleotide, Biotechnology, Microarrays, Integrated DNA Technologies, Bridged nucleic acid
Tuesday, November 24, 2020 - 4:21pm

The growth of the oligonucleotide synthesis market is due to the increasing government investments and R&D expenditure in pharmaceutical and biotechnology companies and the use of synthesized oligonucleotides in molecular diagnostics and clinical applications.

Key Points: 
  • The growth of the oligonucleotide synthesis market is due to the increasing government investments and R&D expenditure in pharmaceutical and biotechnology companies and the use of synthesized oligonucleotides in molecular diagnostics and clinical applications.
  • The usage of synthetic oligonucleotides has been increasing rapidly over the past decade, owing to several benefits offered by molecular diagnostics and growing clinical applications.
  • Synthetic oligonucleotides also have significant clinical applications, primarily for the detection of autoimmune antibodies.
  • Thus, all these factors are responsible for the growth of the oligonucleotide synthesis market.

Global Direct-to-Consumer Genetic Testing Markets Insights to 2025 - ResearchAndMarkets.com

Health, Genetics, Branches of biology, Biology, Life sciences, Molecular biology, Biotechnology, DNA sequencing, DNA, Medical genetics, Genotyping, Genetic testing, Polymerase chain reaction, Massive parallel sequencing
Tuesday, November 24, 2020 - 4:04pm

The "Direct-to-Consumer Genetic Testing: Global Markets and Technologies" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Direct-to-Consumer Genetic Testing: Global Markets and Technologies" report has been added to ResearchAndMarkets.com's offering.
  • The scope of this report includes DTC genetic testing technologies, applications, industry subsegments, major strategic alliances, patents, and companies.
  • This report reviews the main DTC genetic testing technologies, including next-generation sequencing (NGS), polymerase chain reaction (PCR), and genotyping microarrays.
  • The report then discusses several of the significant large-scale population sequencing initiatives that are contributing to DTC genetic testing development.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Biogen, Inc. (BIIB) Investors

Legal, Professional services, Monoclonal antibodies, Biogen, Spinal muscular atrophy, Life sciences, Aducanumab, Drugs, Biotechnology
Tuesday, November 24, 2020 - 4:00pm

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Biogen, Inc. (Biogen or the Company) (NASDAQ: BIIB ) securities between October 22, 2019 and November 6, 2020, inclusive (the Class Period).

Key Points: 
  • Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Biogen, Inc. (Biogen or the Company) (NASDAQ: BIIB ) securities between October 22, 2019 and November 6, 2020, inclusive (the Class Period).
  • Biogen investors have until January 12, 2021 to file a lead plaintiff motion.
  • Investors suffering losses on their Biogen investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com .
  • One of its product candidates is aducanumab (BIIB037), an investigational human monoclonal antibody studied for use as a treatment for early Alzheimers disease.

Existing guidance appropriate for assessment of genome editing in plants

Branches of biology, Life sciences, Biology, Biotechnology, Molecular biology, Biological engineering, Emerging technologies, Genome editing, Genetically modified organisms, Mutagenesis, Genetic engineering, Genetic engineering techniques
Tuesday, November 24, 2020 - 4:04pm

Genome editing techniques that modify the DNA of plants do not pose more hazards than conventional breeding or techniques that introduce new DNA into a plant, an EFSA assessment concludes.

Key Points: 
  • Genome editing techniques that modify the DNA of plants do not pose more hazards than conventional breeding or techniques that introduce new DNA into a plant, an EFSA assessment concludes.
  • The scientific opinion focuses on plants produced using different genome editing techniques: site-directed nuclease-1 (SDN-1), site-directed nuclease-2 techniques (SDN-2) and oligonucleotide-directed mutagenesis (ODM).
  • Experts concluded that the existing guidance for risk assessment of genetically modified plants is applicable for the evaluation of the three new techniques.
  • Genome editing changes the DNA of animals, plants and microorganisms with high precision.

Venatorx Pharmaceuticals Names Robert Waltermire, Ph.D. Senior Vice President, CMC

Health, Other Health, Other Science, Research, Pharmaceutical, Science, Articles, Health sciences, Life sciences, Antimicrobial resistance, Evolutionary biology, Pharmaceuticals policy, Veterinary medicine, Antiviral drug, Antibiotic
Tuesday, November 24, 2020 - 3:00pm

Venatorx Pharmaceuticals today announced that Robert Waltermire, Ph.D. has joined the Company as Senior Vice President, Chemistry, Manufacturing and Controls (CMC).

Key Points: 
  • Venatorx Pharmaceuticals today announced that Robert Waltermire, Ph.D. has joined the Company as Senior Vice President, Chemistry, Manufacturing and Controls (CMC).
  • Robs broad experience, from pre-clinical and clinical development through large scale manufacturing processes, will be invaluable for our antibiotic and antiviral programs.
  • Prior to joining Venatorx, Dr. Waltermire was Senior Vice President, Product Development at Palatin Technologies where he led a global team to deliver on all aspects of the generation of knowledge and product for both clinical development and commercial sale.
  • Venatorx Pharmaceuticals is a private pharmaceutical company focused on improving health outcomes for patients with multi-drug-resistant bacterial infections and hard-to-treat viral infections.

DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

Legal, Professional services, BioMarin Pharmaceutical, Virotherapy, Securities Class Action, Financial markets, Securities regulation in the United States, Life sciences, Companies
Tuesday, November 24, 2020 - 2:13pm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BioMarin Pharmaceutical Inc. (BioMarin or the Company) (NASDAQ: BMRN ) for violations of the securities laws.

Key Points: 
  • The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BioMarin Pharmaceutical Inc. (BioMarin or the Company) (NASDAQ: BMRN ) for violations of the securities laws.
  • The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
  • BioMarins Phase 3 trial of valoctocogene roxaparvovec differed from its Phase 1/2 trial, which lowered the reliability of the earlier studys data on durability of effect.
  • The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

Elevian Announces $15 Million Equity Financing

GDF11, Biotechnology, Biology, Life sciences
Tuesday, November 24, 2020 - 2:00pm

ALLSTON, Mass., Nov. 24, 2020 /PRNewswire/ -- Elevian , an emerging biotech company developing medicines that restore youthful regenerative capacity with the potential to treat and prevent multiple age-related diseases, today announced the closing of a $15 million equity financing.

Key Points: 
  • ALLSTON, Mass., Nov. 24, 2020 /PRNewswire/ -- Elevian , an emerging biotech company developing medicines that restore youthful regenerative capacity with the potential to treat and prevent multiple age-related diseases, today announced the closing of a $15 million equity financing.
  • Proceeds from the equity financing will enable Elevian to advance recombinant GDF11 (rGDF11) toward the clinic to treat stroke and other age-related diseases.
  • In conjunction with the financing, Elevian has appointed Suzanne Fletcher and Dan Marshak to its board of directors.
  • Elevian is an emerging biotech company developing medicines that restore youthful regenerative capacity, with the potential to treat and prevent multiple age-related diseases.

OncoSec Announces Exclusive License Agreement for Cliniporator® Gene Electrotransfer Platform Developed by IGEA Clinical Biophysics

Biology, Biotechnology, Life sciences, Electroporation, Gene delivery, Microbiology, Molecular biology, Natural sciences
Tuesday, November 24, 2020 - 2:00pm

PENNINGTON, N.J. and SAN DIEGO, Nov. 24, 2020 /PRNewswire/ --OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a late-stage biotechnology company developing intra-tumoral cancer immunotherapies, today announced that it has licensed the exclusive rights to the Cliniporator electroporation or gene electrotransfer platform from IGEA Clinical Biophysics ("IGEA").

Key Points: 
  • PENNINGTON, N.J. and SAN DIEGO, Nov. 24, 2020 /PRNewswire/ --OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a late-stage biotechnology company developing intra-tumoral cancer immunotherapies, today announced that it has licensed the exclusive rights to the Cliniporator electroporation or gene electrotransfer platform from IGEA Clinical Biophysics ("IGEA").
  • The license encompasses a broad field of use for gene delivery in oncology, including use as part of OncoSec's visceral lesion applicator (VLA) program.
  • IGEA has clinical experience with gene therapy as well, which OncoSec will build on.
  • Ruggero Cadossi, M.D., IGEA President, added, "We are proud to collaborate with OncoSec, a company committed to delivering innovative therapies to cancer patients.

Twist Bioscience to Present at Upcoming Virtual Investor Conferences

Technology, Research, Genetics, Nanotechnology, Biotechnology, Health, Pharmaceutical, Other Science, Science, Articles, Twist Bioscience, Branches of biology, Life sciences, Synthetic biology, Evercore, Genomics
Tuesday, November 24, 2020 - 1:00pm

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will present at the following upcoming virtual investor conferences:

Key Points: 
  • Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will present at the following upcoming virtual investor conferences:
    Piper Sandler 32nd Annual Virtual Healthcare Conference, recorded fireside chat available at 8:00 a.m.
  • ET on Monday, November 30
    2020 Evercore ISI HealthCONx Conference on Tuesday, December 1 at 1:50 p.m.
  • ET
    Both presentations can be accessed by visiting the Investor Calendar page of the investor relations section of the companys website here .
  • Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology.